Cite
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients.
MLA
Gambato, Martina, et al. “THU-141-Efficacy and Safety of Elbasvir/Grazoprevir in a Large Real-Life Cohort of HCV-Infected Patients.” Journal of Hepatology, vol. 70, Apr. 2019, pp. e223–24. EBSCOhost, https://doi.org/10.1016/S0618-8278(19)30416-5.
APA
Gambato, M., Spinetti, A., Pasulo, L., D’ambrosio, R., Puoti, M., Schiavini, M., Fabris, P., Sacchi, P., Gulminetti, R., Carolo, G., Scotton, P., Pozzan, C., Vinci, M., Viganò, M., Lobello, S., Zuin, M. G., Aghemo, A., Rumi, M. G., Carrara, M., & Manfrin, V. (2019). THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients. Journal of Hepatology, 70, e223–e224. https://doi.org/10.1016/S0618-8278(19)30416-5
Chicago
Gambato, Martina, Angiola Spinetti, Luisa Pasulo, Roberta D’ambrosio, Massimo Puoti, Monica Schiavini, Paolo Fabris, et al. 2019. “THU-141-Efficacy and Safety of Elbasvir/Grazoprevir in a Large Real-Life Cohort of HCV-Infected Patients.” Journal of Hepatology 70 (April): e223–24. doi:10.1016/S0618-8278(19)30416-5.